Application of Cardiac Neurohormonal Imaging to Heart Failure, Transplantation, and Diabetes

Current Cardiovascular Imaging Reports

Volumn 8, Issue 4, 2015, Pages

  Travin, Mark I ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

123I mIBG; Autonomic imaging; Cardiac transplant; Diabetes mellitus; Heart failure

Indexed keywords

(3 IODOBENZYL) GUANIDINE I 123; 11C HYDROXYEPHEDRINE; CREATININE; SODIUM; TRACER; UNCLASSIFIED DRUG;

AUTONOMIC DYSFUNCTION; AUTONOMIC NERVOUS SYSTEM; CARDIAC IMAGING; CARDIAC NEUROHORMONAL IMAGING; CARDIOVASCULAR PARAMETERS; COLLIMATOR; COMPUTER ASSISTED DIAGNOSIS; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART TO MEDIASTINAL RATIO; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LEFT VENTRICULAR ASSIST DEVICE; METHODOLOGY; NEW YORK HEART ASSOCIATION CLASS; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRACER WASHOUT RATE; VENTRICULAR ASSIST DEVICE; VENTRICULAR PACEMAKER;

EID: 84923795266     PISSN: 19419066     EISSN: 19419074     Source Type: Journal    
DOI: 10.1007/s12410-015-9323-3     Document Type: Review

References (100)

1. Bell DR. Control mechanisms in circulatory function. In: Rhoades RA, Bell DR, editors. Medical physiology: principles of clinical medicine. 4th ed. Philadelphia: Lippincott, Williams & Wilkins; 2013. p. 317–20.
2. Colucci WS. Pathophysiology of heart failure: Neurohumoral adaptations. http://www.uptodate.com/contents/pathophysiology-of-heart-failure-neurohumoral-adaptations, accessed 7/2/2014; topic last updated September 19, 2013.
3. Francis GS. Neurohormonal control of heart failure. Cleve Clin J Med. 2011;78:S75–9.
4. Zipes DP. Autonomic modulation of cardiac arrhythmias. In: Zipes DP, Jalife J, editors. Cardiac electrophysiology: from cell to bedside. 2nd ed. Philadelphia: W.B. Saunders Company; 1995. p. 441–2.
5. Carrió I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062–76.
6. Travin MI. Cardiac neuronal imaging at the edge of clinical application. Cardiol Clin. 2009;27:311–27.
7. Verrier RL, Antzelevich C. Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol. 2004;19:2–11.
8. Sisson JC, Wieland DM. Radiolabeled meta-iodobenzylguanidine pharmacology: pharmacology and clinical studies. Am J Physiol Imaging. 1986;1:96–103.
9. Wieland DM, Mangner TJ, Inbasekaran MN, et al. Adrenal medulla imaging agents: a structure-distribution relationship study of radiolabeled aralkylguanidines. J Med Chem. 1984;27:149–55.
10. Kline RC, Swanson DP, Wieland DM, et al. Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J Nucl Med. 1981;22:129–32.
11. Raffel DM, Wieland DM. Development of mIBG as a cardiac innervation imaging agent. J Am Coll Cardiol Img. 2010;3:111–6.
12. 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging. 2010;37:1802–12.
13. Jacobson AF, Lombard J, Banerjee G, Camici PG. 123I-mIBG scintigraphy to predict risk for adverse cardiac outcomes in heart failure patients: design of two prospective multicenter international trials. J Nucl Cardiol. 2009;16:113–21.
14. Tilkemeier PL, Wackers FJT. Myocardial perfusion planar imaging. J Nucl Cardiol. 2006;13:e91–6.
15. Holly TA, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. J Nucl Cardiol. 2010;17:941–73.
16. Verberne HJ, Feenstra C, de Jong WM, et al. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging. 2005;32:1100–7.
17. 123I-MIBG scintigraphic study. J Nucl Med. 2000;41:845–51.
18. Gerson MC, Craft LL, McGuire N, et al. Carvedilol improves left ventricular function in heart failure with idiopathic dilated cardiomyopathy and a wide range of sympathetic nervous system function as measured by iodine 123 metaiodobenzylguanidine. J Nucl Cardiol. 2002;9:608–15.
19. Yamada T, Shimonagata T, Fukunami M, et al. Comparison of the prognostic value of cardiac iodine-123 metaiodobenzylguanidine imaging and heart rate variability in patients with chronic heart failure. J Am Coll Cardiol. 2003;41:231–8.
20. Hattori N, Schwaiger M. Metaiodobenzylguanidine scintigraphy of the heart. What have we learned clinically? Eur J Nucl Med. 2000;27:1–6.
21. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55:2212–21.
22. Chen GP, Tabibiazar R, Branch KR, et al. Cardiac receptor physiology and imaging: an update. J Nucl Cardiol. 2005;12:714–30.
23. Morozumi T, Kusuoka H, Fukuchi K, et al. Myocardial iodine-123-metaiodobenzylguanidine images and autonomic nerve activity in normal subjects. J Nucl Med. 1997;38:49–52.
24. Ogita H, Shimonagata T, Fukunami M, et al. Prognostic significance of cardiac 123I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure: a prospective study. Heart. 2001;86:656–60.
25. Veltman CE, Boogers MJ, Meinardi JE, et al. Reproducibility of planar 123I-meta-iodobenzylguanidine (MIBG) myocardial scintigraphy in patients with heart failure. Eur J Nucl Med Mol Imaging. 2012;39:1599–608.
26. Minardo JD, Tuli MM, Mock BH, et al. Scintigraphic and electrophysiologic evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation. 1988;78:1008–19.
27. 123I-mIBG Scintigraphy to predict inducibility of ventricular arrhythmias on cardiac electrophysiology testing: a prospective multicenter pilot study. Circ Cardiovasc Imaging. 2008;1:131–40.
28. Boogers MJ, Borleffs CJ, Henneman MM, et al. Cardiac sympathetic denervation assessed with 123-iodine metaiodobenzylguanidine imaging predicts ventricular arrhythmias in implantable cardioverter-defibrillator patients. J Am Coll Cardiol. 2010;55:2769–77.
29. Marshall A, Cheetham A, George RS, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts ventricular arrhythmia in heart failure patients receiving an implantable cardioverter-defibrillator for primary prevention. Heart. 2012;98:1359–65.
30. 99mTc-tetrofosmin SPECT for the prediction of arrhythmic events in ischemic heart failure patients. J Nucl Cardiol. 2014;21:799. abstract.
31. Go AS, Mozaffarian D, Roger VL, On behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee, et al. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–292.
32. Flotats A, Carrió I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11:587–602.
33. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 1988;12:1252–8.
34. Merlet P, Valette H, Dubois-Randé J, et al. Prognostic value of cardiac metaiodobenzylguanidine in patients with heart failure. J Nucl Med. 1992;33:471–7.
35. Nakata T, Miyamoto K, Doi A, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol. 1998;5:579–90.
36. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29:1147–59.
37. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35:535–46.
38. Nakata T, Nakajima K, Yamashina S, et al. A pooled analysis of multicenter cohort studies of I-123-mIBG cardiac sympathetic innervation imaging for assessment of long-term prognosis in chronic heart failure. J Am Coll Cardiol Img. 2013;6:772–84.
39. Shaw LJ, Min JK, Hachamovitch R, et al. Cardiovascular imaging research at the crossroads. J Am Coll Cardiol Imaging. 2010;3:316–24.
40. Treglia G, Stefanelli I, Giordano BA. Clinical usefulness of myocardial innervation imaging using iodine-123-meta-iodobenzylguanidine scintigraphy in evaluating the effectiveness of pharmacological treatments in patients with heart failure: an overview. Eur Rev Med Pharmacol Sci. 2013;17:56–8.
41. Toyama T, Aihara Y, Iwasaki T, et al. Cardiac sympathetic activity estimated by 123I-MIBG myocardial imaging in patients with dilated cardiomyopathy after β-blocker or angiotensin-converting enzyme inhibitor therapy. J Nucl Med. 1999;40:217–23.
42. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med. 1997;38:1085–9.
43. Kasama S, Toyama T, Kumakura H, et al. Addition of valsartan to an angiotensin-converting enzyme inhibitor improves cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure. J Nucl Med. 2003;44:884–90.
44. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with congestive heart failure. J Nucl Med. 2002;43:1279–85.
45. Choi JY, Lee KH, Hong KP, et al. Iodine-123 MIBG imaging before treatment of heart failure with carvedilol to predict improvement of left ventricular function and exercise capacity. J Nucl Cardiol. 2001;8:4–9.
46. Udelson JE, Shafer CD, Carrió I. Radionuclide imaging in heart failure: assessing etiology and outcomes and implications for management. J Nucl Cardiol. 2002;9:S40–52.
47. Jessup M, Abraham WT, Casey DE, Writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;53:1343–82.
48. Kremers MS, Hammill SC, Berul CI, et al. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013;10:e59–65.
49. Myerburg RJ. Implantable cardioverter-defibrillators after myocardial infarction. N Engl J Med. 2008;359:2245–53.
50. Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res. 2004;95:754–63.
51. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to De Novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol. 2010;55:774–82.
52. Vollmann D, Lüthje L, Vonhof S, Unterberg C. Inappropriate therapy and fatal proarrhythmia by an implantable cardioverter-defibrillator. Heart Rhythm. 2005;2:307–9.
53. McGhie AI, Corbett JR, Akers MS, et al. Regional cardiac adrenergic function using I-123 MIBG SPECT imaging after acute myocardial infarction. Am J Cardiol. 1991;67:236–42.
54. Stanton MS, Tuli MM, Radtke NL, et al. Regional sympathetic denervation after MI in humans detected noninvasively using I-123-MIBG. J Am Coll Cardiol. 1989;14:1519–26.
55. Gerson MC, Abdallah M, Muth JN, Costea AI. Will imaging assist in the selection of patients with heart failure for an ICD? J Am Coll Cardiol Imaging. 2010;3:101–10.
56. Arora R, Ferrick KJ, Nakata T, et al. I-123 MIBG imaging and heart rate variability analysis to predict the needs for an implantable cardioverter defibrillator. J Nucl Cardiol. 2003;10:121–31.
57. Nagahara D, Nakata T, Hashimoto A, et al. Predicting the need for an implantable cardioverter defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med. 2008;49:225–33.
58. 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. J Nucl Med. 2008;49:907–14.
59. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53:426–35.
60. Passman R, Goldberger JJ. Predicting the future: risk stratification for sudden cardiac death in patients with left ventricular dysfunction. Circulation. 2012;125:3031–7.
61. Buxton AE. Not everyone with an ejection fraction ≤30% should receive an ICD. Circulation. 2005;111:2537–49.
62. Shah AM, Bourgoun M, Narula J, et al. Influence of ejection fraction on the prognostic value of sympathetic innervation imaging with iodine-123 MIBG in heart failure. J Am Coll Cardiol Img. 2012;5:1139–46. A subanalysis of ADMIRE-HF data showing that 123I-mIBG imaging also has risk stratification utility in patients with LVEFs ≥35%.
63. Inoue H, Zipes DP. Results of sympathetic denervation in the canine heart: supersensitivity that may be arrhythmogenic. Circulation. 1987;75:877–87.
64. Fallavollita JA, Canty JM. Dysinnervated but viable myocardium in ischemic heart disease. J Nucl Cardiol. 2010;17:1107–15.
65. Simões MV, Barthel P, Matsunari I, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25:551–7.
66. Luisi Jr AJ, Suzuki G, Dekemp R, et al. Regional 11C-hydroxyephedrine retention in hibernating myocardium: chronic inhomogeneity of sympathetic innervation in the absence of infarction. J Nucl Med. 2005;46:1368–74.
67. Fallavollita JA, Heavey BM, Luisi Jr AJ, et al. Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol. 2014;63:141–9. A study of patients with hibernating myocardium showing that adrenergic imaging, here with the PET tracer 11C-HED, is effective at identifying patient at increased risk of life threatening arrhythmic events.
68. Sinusas AJ, Lazewatsky J, Brunetti J, et al. Biodistribution and radiation dosimetry of LMI1195: first-in-human study of a novel 18F-labeled tracer for imaging myocardial innervation. J Nucl Med. 2014;55:1–7.
69. Matsui T, Tsutamoto T, Maeda K, et al. Prognostic value of repeated 123I-metaiodobenzylguanidine imaging in patients with dilated cardiomyopathy with congestive heart failure before and after optimized treatments—comparison with neurohumoral factors. Circ J. 2002;66:537–43.
70. Tracy CM, Epstein AE, Darbar D, et al. 2012 ACCF/AHA/HRS focused update of the 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2012;60:1297–313.
71. Scholtens AM, Braat AJ, Tuinenburg A, et al. Cardiac sympathetic innervation and cardiac resynchronization therapy. Heart Fail Rev 2013 Jun 9.
72. 123I-MIBG myocardial scintigraphy. J Nucl Cardiol. 2007;14:852–9.
73. Tanaka H, Tatsumi K, Fujiwara S, et al. Effect of left ventricular dyssynchrony on cardiac sympathetic activity in heart failure patients with wide QRS duration. Circ J. 2012;76:382–9.
74. Erol-Yilmaz A, Verberne HJ, Schrama TA, et al. Cardiac resynchronization induces favorable neurohumoral changes. Pacing Clin Electrophysiol. 2005;28:304–10.
75. Higuchi K, Toyama T, Tada H, et al. Usefulness of biventricular pacing to improve cardiac symptoms, exercise capacity and sympathetic nerve activity in patients with moderate to severe chronic heart failure. Circ J. 2006;70:703–9.
76. Gould PA, Kong G, Kalff V, et al. Improvement in cardiac adrenergic function post biventricular pacing for heart failure. Europace. 2007;9:751–6.
77. Miyagawa S, Sawa Y, Fukushima N, et al. Analysis of sympathetic nerve activity in end-stage cardiomyopathy patients receiving left ventricular support. J Heart Lung Transplant. 2001;20:1181–7.
78. Drakos SG, Athanasoulis T, Malliaras KG, et al. Myocardial sympathetic innervation and long-term left ventricular mechanical unloading. J Am Coll Cardiol Img. 2010;3:64–70.
79. George RS, Birks EJ, Cheetham A, et al. The effect of long-term left ventricular assist device support on myocardial sympathetic activity in patients with non-ischaemic dilated cardiomyopathy. Eur J Heart Fail. 2013;15:1035–43. A small pilot study showing that 123I-mIBG imaging may help identify patents who are candidates for LVADs explantation.
80. Mancini D, Lietz K. Selection of cardiac transplantation candidates in 2010. Circulation. 2010;1222:173–83.
81. O’Neill J, Young J, Pothier C, Lauer M. Peak oxygen consumption as a predictor of death in patients with heart failure receiving beta blockers. Circulation. 2005;111:2313–8.
82. Aaronson K, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660–7.
83. Levy WC, Mozaffarian D, Linker DT, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424–33.
84. Cohen-Solal A, Esanu Y, Logeart D, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol. 1999;33:759–660.
85. Gerson MC, McGuire N, Wagoner LE. Sympathetic nervous system function as measured by I-123 metaiodobenzylguanidine predicts transplant-free survival in heart failure patients with idiopathic dilated cardiomyopathy. J Card Fail. 2003;9:384–91.
86. Ketchum ES, Jacobson AF, Caldwell JH, et al. Selective improvement in Seattle Heart Failure Model risk stratification using iodine-123 meta-iodobenzylguanidine imaging. J Nucl Cardiol. 2012;19:1007–16.
87. 123I-mIBG data of 636 patients from 6 European and US sites showing the utility of imaging for predicting a variety of adverse cardiac events, but that planar HMR may be less useful for predicting arrhythmic events.
88. Flotats A, Carrió I. Value of radionuclide studies in cardiac transplantation. Ann Nucl Med. 2006;20:13–21.
89. Di Carli MF, Tobes MC, Mangner T, et al. Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med. 1997;336:1208–15.
90. 123I-MIBG imaging. J Nucl Med. 1999;40:911–6.
91. Bengel FM, Ueberfuhr P, Schiepel N, et al. Effect of sympathetic reinnervation on cardiac performance after heart transplantation. N Engl J Med. 2001;345:731–8.
92. Gerson MC, Caldwell JH, Ananthasubramaniam K, et al. Influence of diabetes mellitus on prognostic utility of imaging of myocardial sympathetic innervation in heart failure patients. Circ Cardiovasc Imaging. 2011;4:87–93. A study of about 1000 patients showing that in diabetic heart failure patients an HMR <1.6 is associated with an almost threefold increase in heart failure progression. Thus, therapies that prevent or ameliorate identified cardiac denervation in these patients may be a beneficial addition to therapies focused primarily on the diabetes.
93. Lee K-H, Jang H-J, Lee EJ, et al. Prognostic value of cardiac autonomic neuropathy independent and incremental to perfusion defects in patients with diabetes and suspected coronary artery disease. Am J Cardiol. 2003;92:1458–61.
94. Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001;24:1793–8.
95. Langer A, Freeman MR, Josse RG, et al. Metaiodobenzylguanidine imaging in diabetes mellitus: assessment of cardiac sympathetic denervation and its relation to autonomic dysfunction and silent myocardial ischemia. J Am Coll Cardiol. 1995;25:610–8.
96. Hattori N, Tamaki N, Hayashi T, et al. Regional abnormality of iodine-123-MIBG in diabetic hearts. J Nucl Med. 1996;37:1985–90.
97. Stevens MJ, Raffel DM, Allman KC, et al. Cardiac sympathetic dysinnervation in diabetes. Implications for enhanced cardiovascular risk. Circulation. 1998;98:961–8.
98. Sacre JW, Franjic B, Jellis CL, et al. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes. JACC Cardiovasc Imaging. 2010;3:1207–15.
99. Nagamachi S, Fujita S, Nishii R, et al. Prognostic value of cardiac I-123 metaiodobenzylguanidine imaging in patients with non-insulin-dependent diabetes mellitus. J Nucl Cardiol. 2006;13:34–42.
100. 123I meta-iodobenzylguanidine (123I MIBG) scintigraphic study. Diabetes Care. 2013;36:2395–401.